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Abstract—A convenient synthetic approach to polysubstituted dihydrogenated or heteroaromatic 1,2,4-triazolo-
[1,5-a]pyrimidines derivatives containing at position 5 a 4-methylpyrimidine moiety bearing a cycloamino sub-
stituent at position 2 and linked to the triazolopyrimidine bicycle through its position 5 was developed. The 
approach involves unusual three-component condensations of 3-amino-1,2,4-triazoles, methyl 3-(2-R-4-me-
thylpyrimidin-5-yl)-3-oxopropionates, and a series of C1 synthons whose synthetic equivalents are a series of 
aromatic aldehydes, triethyl orthoformate, or DMFDMA were used as of C1 synthons.
Keywords: triazolopyrimidine, 4-methylpyrimidine, 1,3-ketocarboxylic acid ester, C1 synthon, three-component 
condensation, molecular hybridization, regioselectivity
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INTRODUCTION
In the context of the search for new hybrid multitarget 
molecules [1] containing fragments, one of which would 
have an antibacterial and the other an anticoagulant 
activity, we proposed to combine 1,2,4-triazolo[1,5-a]-
pyrimidine and 2-cycloalkylamino-substituted pyri-
midine scaffolds (Fig. 1).
The fi rst components of the system I is a partially 
hydrogenated or heteroaromatic 1,2,4-triazolo[1,5-a]-
pyrimidine bicycle I is interesting as a scaffold with 
pronounced antibacterial and anticancer properties [2]. 
Moreover, over the past years 1,2,4-triazolo[1,5-a]-
pyrimidine derivatives have been considered as as 
promising reverse transcriptase inhibitors of a number 
of viruses [3]. The second component of the system II 
is a 2-cycloamino-4-methylpyrimidine fragment linked 
through its position 5 to position 5 of the triazolopyrimi-
dine bicycle. Such scaffolds present interest primarily as 
an inhibitor of the endothelin converting enzyme 1 [4] 
and vascular adhesion protein [5], and, consequently, can 
be considered as quite promising scaffolds for the design 
of new anticoagulants. Furthermore, 2-cycloamino-4-
methylpyrimidines can act as an activator of the insulin-
like growth factor receptor [6] and an inhibitor of some 
phosphodiesterases [7].
Three-component reactions of 1,3-dicarbonyl 
compounds with 3-amino-1,2,4-triazoles and aldehydes 
[8–12], orthoformates, or dimethylformamide dimethyl 
acetal (DMPDMA) [9, 13–15] are described in the 
literature and are convenient methods for the formation 
of polysubstituted triazolopyrimidine systems.
RESULTS AND DISCUSSION
In the present work we extended this approach to our 
earlier synthesized methyl 3-(2-R-4-methylpyrimidin-
5-yl)-3-oxopropionates 1a and 1b, which were reacted 
with aromatic aldehydes 2a and 2b and 5-R-3-amino-
1,2,4-triazoles 3a and 3b (Scheme 1). After prolonged 
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refl uxing of an equimolar mixture of the reagents in 
isopropanol or dioxane gives we isolated products
4a–4d in yields of 48–64%. It was found that the nature 
of the solvent only slightly affects the yield and time of 
the reaction.
The 1H NMR spectra of compounds 4a–4d contain 
signals of the aromatic protons of the aryl rings at 
6.88–7.60 ppm and characteristic proton signals of the 
methoxycarbonyl groups at ~3.70 ppm. The NH and 



























































































Ar = C6H5 (2a, 4a, 4b), 4-CH3O-C6H4 (2b, 4c, 4d), R2 = H (3a, 4a, 4c), CH3 (3b, 4b, 4d).
R1 =                    (1a, 4a, 4c);                         (1b, 4b, 4d);N NO
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appear at ~12.00 and 5.45 ppm, respectively. The proton 
signals of the triazole and pyrimidine rings are observed 
at 7.82 and 8.79 ppm, respectively. The mass spectra 
of compounds 4a–4d contain protonated molecular ion 
peaks. These data allow the synthesized products to be 
assigned the structure of methyl 5-(4-methyl-2-R-py-
rimidin-5-yl)-7-aryl-4,7-dihidro[1,2,4]triazolo[1,5-a]-
pyrimidine-6-carboxylates 4a–4d.
We suggest that the reaction starts with a 
Knoevenagel-type condensation of esters 1 with alde-
hydes to form intermediate arylidene derivatives A. 
The subsequent addition of the endocyclic NH group of 
aminotriazoles 3 at the C=C double bond of intermediate 
A leads to intermediate adduct B. The latter undergoes 
heterocyclization at the aminotriazole exocyclic amino 
group, yielding the fi nal pyrimidin-5-yltriazolo[1,5-a]-
pyrimidines 4.
Attempted synthesis by this three-component 
condensation of 7-unsubstituted esters of 5-(4-methyl-
2-R-pyrimidin-5-yl)-4,7-dihydro[1,2,4]triazolo[1,5-a]-
pyrimidine-6-carboxylic acids, with formaldehyde as 
the aldehyde component, failed. It was found that the 
main product of this reaction was compound 5 formed 
by the reaction of formaldehyde with two molecules of 
methyl 3-[4-methyl-2-(piperidin-1-yl)pyrimidin-5-yl]-
3-oxopropionate (1c) (Scheme 2).
The 1H NMR spectrum of compound 5 contains 
exclusively characteristic proton signals of methyl
3-[4-methyl-2-(piperidin-1-yl)pyrimidin-5-yl]-3-oxo-
propionate fragments tethered by a methylene group, 
the protons of which give two multiplets at 1.95–2.02 
and 2.15–2.19 ppm. The mass spectral data, too, provide 
evidence for the proposed dimethyl 2,4-bis[4-methyl-
2-(piperidin-1-yl)pyrimidin-5-ylcarbonyl]glutarate (5) 
structure (Fig. 2).
With DMFDMA as an analog of the aldehyde 
component, the reactions of 3-(4-methyl-2-R-pyrimidin-
5-yl)-3-oxopropionic acid esters 1a–1c and 5-amino-
1,2,4-triazoles 3a–3c gave hardly separable mixtures of 
products. However, when the reactions were performed 
consecutively, we were able to direct the process to 
the formation of three-component reaction products, 
specifi cally methyl 7-(2-R-4-methylpyrimidin-5-yl)-
2-R1-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylates 
6a–6e (Scheme 3).
The 1H NMR spectra of compounds 6 display 
singlet signals of the methoxycarbonyl group protons 
at 3.65–3.78 ppm and proton signals of the newly 
formed pyrimidine ring at 8.82–9.39 ppm. In addition, 
the spectra show proton signals of the unsubstituted 
triazole ring (compounds 6a and 6c) at 8.24 ppm, and 
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It can be assumed that enaminone B formed at 
the fi rst stage reacts with 5-aminotriazole with the 
elimination of dimethylamine, and, therewith, this 
reaction involves the most reactive exocyclic amino 
group of aminotriazole. Intermediate C formed at this 
stage undergoes cyclization into the fi nal product 6 
via the reaction of the endocyclic amino and carbonyl 
groups, with the elimination of a water molecule.
EXPERIMENTAL
The 1H NMR spectra of the synthesized compounds 
were registered on a Bruker DRX-500 spectrometer 
(500 MHz) in DMSO-d6, internal reference TMS. The 
LC-MS analysis was performed on an Agilent Agilent 
1260 Infi nity 6230 TOF LC/MS system with a dual ESI 
source, operated in the positive ion mode; nebulizer 
gas (N2) 20 psig, desiccant gas (N2) 6 mL/min, 325°C; 
mass range is 50–2000 Da. Capillary voltage 4.0 kV, 
fragmentor voltage +191 V, skimmer voltage +66 V, 
and OctRF voltage 750 V. Chromatography conditions: 
Poroshell 120 EC-C18 column (4.6×50 mm, 2.7 μm), 
gradient elution acetonitrile–water (0.1% formic acid), 
fl ow rate 0.4 mL/min. An Agilent MassHunter Data 
Acquisition Software (version B.06.00) was used for 
data processing. The melting points were measured on 
a Stuart SMP30 apparatus. The purity of reagents and 
synthesized compounds, as well as reaction progress 
were monitored by TLC on Merck Silica gel 60 F254 
plates, eluent CHCl3–MeOH, 10 : 1 (spot development 
by exposure to UV light).
The starting 3-(2-R-4-methylpyrimidin-5-yl)-3-
oxopropionic acid esters 1a–1c were synthesized by the 
procedure described in our previous work [16].
Methyl 5-(4-methyl-2-R-pyrimidin-5-yl)-7-aryl-
4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidine-6-car-
boxylates 4a–4d (general procedure). A mixture of 
4 mmol of ester 1a or 1b, 4 mmol of aldehyde 2a or 
2b, and 4 mmol of 3-amino-1,2,4-triazole 3a or 3b 
was heated under refl ux in 5 mL ofi sopropanol for
4 h. After cooling, a precipitate formed and was fi ltered 




pyrimidine-6-carboxylate (4a). Yield 1.07 g (64%), 
fi ne white needles, mp 195–197°C. 1H NMR spectrum 
(DMSO-d6), δ, ppm: 1.49–1.55 m (4H, CH2CH2pyrrolid), 
2.59 s (3H, CH3), 3.70 s (3H, CH3O), 3.81–3.92 m (4H, 
CH2NCH2), 5.45 s (1H, CH), 6.93 t (1Harom, J 7.8 Hz), 
7.19–7.23 m (2Harom), 7.58–7.61 m (2Harom), 7.82 s (1H, 
Htriaz), 8.79 s (1H, Hpyrimid), 11.98 s (1H, NH). Mass 
spectrum, m/z: 418.1995 [M + H]+. C22H23N7O2. [M + 
H]+ 418.1987.




























Fig. 2. HPLC–MS analysis of compound 5.
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Methyl 2-methyl-5-[4-methyl-2-(morpholin-4-
yl)pyrimidin-5-yl]-7-phenyl-4,7-dihydro[1,2,4]-
triazolo[1,5-a]pyrimidine-6-carboxylate (4b). Yield 
1.04 g (60%), fi ne white needles, mp 184–186°C. 1H 
NMR spectrum (DMSO-d6), δ, ppm: 2.06 s (3H, CH3), 
2.59 s (3H, CH3), 3.70 s (3H, CH3O), 3.82 t (4H, 
CH2NCH2morph, J 8.2 Hz), 3.98 t (4H, CH2OCH2morph, 
J 8.2 Hz), 5.45 s (1H, CH), 6.95 t (1Harom, J 7.8 Hz), 
7.22–7.25 m (2Harom), 7.57–7.61 m (2Harom), 8.79 s 
(1H, Hpyrimid), 11.98 s (1H, NH). Mass spectrum, m/z: 
448.2098 [M + H]+. C23H25N7O3. [M + H]+ 448.2093.
Methyl 7-(4-methoxyphenyl)-5-[4-methyl-2-
(pyrrolidin-1-yl)pyrimidin-5-yl]-4,7-dihydro[1,2,4]-
triazolo[1,5-a]pyrimidine-6-carboxylate (4c). Yield 
0.86 g (48%), fi ne white needles, mp 189–191°C. 1H 
NMR spectrum (DMSO-d6), δ, ppm: 1.49–1.55 m (4H, 
CH2CH2pyrrolid), 2.59 s (3H, CH3), 3.60 s (3H, CH3O), 
3.70 s (3H, CH3O), 3.81–3.92 m (4H, CH2NCH2),
5.45 s (1H, CH), 6.91 d (2Harom, J 7.8 Hz), 7.21 d 
(2Harom, J 7.8 Hz), 7.82 s (1Htriaz), 8.79 s (1H, Hpyrimid), 
11.98 s (1H, NH) Mass spectrum, m/z: 448.2088 [M + 




xylate (4d). Yield 1.03 g (54%), fi ne white needles, mp 
189–200°C. 1H NMR spectrum (DMSO-d6), δ, ppm: 
2.05 s (3H, CH3), 2.59 s (3H, CH3), 3.60 s (3H, CH3O), 
Scheme 3.



























































R2 = H (3a, 6a, 6c), C6H5 (3b, 6b, 6d), CH3S (3c, 6e).
3a–3c
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3.70 s (3H, CH3O), 3.81 t (4H, CH2NCH2morph, J
8.2 Hz), 3.97 t (4H, CH2OCH2morph, J 8.2 Hz), 5.45 s 
(1H, CH), 6.90 d (2Harom, J 7.8 Hz), 7.20 d (2Harom, 
J 7.8 Hz), 8.78 s (1Hpyrimid), 11.97 s (1H, NH). Mass 
spectrum, m/z: 478.2194 [M + H]+. C24H27N7O4. [M + 
H]+ 478.2199.
Dimethyl 2,4-bis{[4-methyl-2-(pyrrolidin-1-yl)-
pyrimidin-5-yl]carbonyl}glutarate (5). A mixture 
of 4 mmol of methyl 3-[4-methyl-2-(pyrrolidin-1-yl)-
pyrimidin-5-yl]-3-oxopropanoate 1c, 4 mmol of 40% 
formaldehyde, and 4 mmol of aminotriazole 3a was 
heated under refl ux in 5 mL of isopropanol for 2 h. 
After cooling, a precipitate formed and was fi ltered 
off and washed with isopropanol. Yield 1.03 g (54%), 
white amorphous material, mp 211–213°C. 1H NMR 
spectrum (DMSO-d6), δ, ppm: 1.49–1.71 m (12H, 
2CH2CH2CH2piperid), 1.95–2.02 m (1H, CH2), 2.15–
2.19 m (1H, CH2), 2.56 s (2H, 2CH3), 3.69 s (6H, 
2CH3O), 3.80–3.94 m (8H, 2CH2NCH2), 5.14–5.16 m 
(2H, 2CH), 8.59 s (2H, Hpyrimid). Mass spectrum, m/z: 
567.2936 [M + H]+. C29H38N6O6. [M + H]+ 567.2928.
Methyl 7-[2-R-4-methylpyrimidin-5-yl]-1,2,4-
triazolo[1,5-a]pyrimidine-6-carboxylate 6a–6e (ge-
neral procedure). A mixture of 6 mmol of 3-(2-R-4-
methylpyrimidin-5-yl)-3-oxopropionic acid ester 1a–1c 
and 6 mmol of DMFDMA was heated under refl ux in
6 mL of isopropanol for 2 h. After cooling, 5 mmol of the 
corresponding 5-amino-1,2,4-triazole 3a–3c was added. 
The precipitate formed after cooling of the reaction 




(6a). Yield 1.20 g (59%), white amorphous material, mp 
182–185°C. 1H NMR spectrum (DMSO-d6), δ, ppm: 
1.51–1.56 m (6H, CH2CH2CH2), 2.16 s (3H, CH3), 
3.65 t (4H, CH2NCH2, J 5.0 Hz), 3.74 s (3H, CH3O), 
8.24 s (1H, CHtriaz), 8.73 s (1H, CHpyrimid), 9.31 s (1H, 
CHpyrimid). Mass spectrum, m/z: 354.1670 [M + H]+. 
C17H19N7O2. [M + H]+ 354.1674.
Methyl 7-[4-methyl-2-(piperidin-1yl)pyrimidin-
5-yl]-2-phenyl-1,2,4-triazolo[1,5-a]pyrimidine-
6-carboxylate (6b). Yield 1.53 g (69%), white 
amorphous material, mp 268–270°C. 1H NMR spectrum 
(DMSO-d6), δ, ppm: 1.51–1.57 m (6H, CH2CH2CH2), 
2.16 s (3H, CH3), 3.76 t (4H, CH2NCH2, J 5.0 Hz),
3.73 s (3H, CH3O), 7.02 t (1Harom, J 7.4 Hz), 7.31 t 
(2Harom, J 8.1 Hz), 7.73 d (2Harom, J 8.1 Hz), 8.78 s (1H, 
CHpyrimid), 9.39 s (1H, CHpyrimid). Mass spectrum, m/z: 
430.1995 [M + H]+. C23H23N7O2. [M + H]+ 430.1987.
Methyl 7-[4-methyl-2-(morpholin-4-yl)pyrimidin-
5-yl]-1,2,4-triazolo[1,5-a]pyrimidine-6-carboxylate 
(6c). Yield 1.13 g (53%), white amorphous material, mp 
268–270°C. 1H NMR spectrum (DMSO-d6), δ, ppm: 
2.14 s (3H, CH3), 3.72 t (4H, CH2NCH2, J 5.0 Hz), 
3.78 s (3H, CH3O), 3.84 t (4H, CH2OCH2, J 5.0 Hz), 
8.24 s (1H, CHtriaz), 8.75 s (1H, CHpyrimid), 8.82 s (1H, 
CHpyrimid). Mass spectrum, m/z: 356.1466 [M + H]+. 
C16H17N7O3. [M + H]+ 356.1466.
Methyl 7-[4-methyl-2-(morpholin-4-yl)pyrimi-
din-5-yl]-2-phenyl-1,2,4-triazolo[1,5-a]pyrimidine-
6-carboxylate (6d). Yield 1.53 g (71%), white 
amorphous material, mp 202–204°C. 1H NMR spectrum 
(DMSO-d6), δ, ppm: 2.13 s (3H, CH3), 3.75 t (4H, 
CH2NCH2, J 5.0 Hz), 3.78 s (3H, CH3O), 3.86 t (4H, 
CH2OCH2, J 5.5 Hz), 7.12 t (1Harom, J 7.4 Hz), 7.40 t 
(2Harom, J 8.1 Hz), 7.76 d (2Harom, J 8.1 Hz), 8.21 s (1H, 
CHpyrimid), 8.84 s (1H, CHpyrimid). Mass spectrum, m/z: 
432.1788 [M + H]+. C22H21N7O3. [M + H]+ 432.1780.
Methyl 7-[4-methyl-2-(pyrrolidin-1-yl)pyrimidin-
5-yl]-2-(methylsulfanyl)-1,2,4-triazolo[1,5-a]py-
rimidine-6-carboxylate (6e). Yield 1.01 g (44%), white 
amorphous material, mp 161–163°C. 1H NMR spectrum 
(DMSO-d6), δ, ppm: 1.53–1.60 m (4H, CH2CH2), 2.15 s
(3H, CH3), 2,38 s (3H, CH3S), 3.78 t (4H, CH2NCH2, 
J 5.8 Hz), 3.77 s (3H, CH3O), 8.76 s (1H, CHpyrimid),
8.87 s (1H, CHpyrimid). Mass spectrum, m/z: 386.1388 
[M + H]+. C17H19N7O2S. [M + H]+ 386.1395.
CONCLUSIONS
A convenient synthetic approach to polysubstituted 
dehydrogenated or heteroaromatic 1,2,4-triazolo[1,5-a]-
pyrimidines containing containing at position 5 a 
4-methylpyrimidine moiety bearing a cycloamino 
substituent at position 2 and linked to the triazo-
lopyrimidine bicycle through its position 5 was 
developed. This allows creation of a target library of 
new hybrid molecules containing in their structure two 
privileged scaffolds, one of which has an antibacterial 
and the other an anticoagulant activity.
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